| Description |
The 5th Annual Biomarkers Congress, presented by Oxford Global Conferences, will provide a first class educational and networking opportunity for over 200 attendees from leading pharmaceutical, biotechnology, diagnostics and clinical research companies as well as academic institutions in the UK, Europe and the US. It will take place on the 25th and 26th February 2010, at the Midland Hotel, Manchester UK.
Over two days the comprehensive scientific conference programme will feature keynote addresses, case study presentations, panel and roundtable discussions from over 40 speakers giving insight on how to effectively manage and streamline your Development process. Topics being covered at the Summit include:-
Biomarker Discovery and Validation: Focus upon methods to accelerate discovery and validation in order to maximise efficiency and reduce costs as well as insight on the regulatory influences of biomarkers and approaches and strategies of the Critical Path Institute
Personalized Medicine Diagnostics and Data Integration: Developing successful integration of these tools within the preclinical and development process
Biomarkers in Clinical Development: Implementing biomarkers as the main drivers of personalised medicine and utilising biomarkers as valuable decision making tools in clinical drug development
Biomarker Discovery & Validation: Therapeutic Case Studies: Ensuring more predictive biomarkers by accessing discovery and validation
techniques in various therapeutic areas
Enabling Technologies to Maximise Biomarker Identification: Examining various imaging techniques to identify biomarkers and critical analysis of other enabling technologies
Confirmed speakers at the event include:-
• Nicholas Dracopoli, Vice President, Biomarkers, Centocor Research & Development
• Duncan McHale, Vice President, Medical Director Personalized Healthcare, AstraZeneca
• Francis Kalush, Network Leader for the Diagnostics (In vivo and In Vitro) and Personalized Medicine Network, FDA
• Miro Venturi, Director Biomarkers and Experimental Medicine, F. Hoffmann La Roche
• Mark Jones, Associate Director Molecular Biomarkers, UCB Group
• David Reynolds, Senior Director, Experimental Biological Sciences, Pfizer
• Roly Foulkes, Vice President Inflammation, UCB
• Martina Kaufmann, Biomarker Project Leader, Head Oncology Biomarkers & Imaging, Novartis
• Huseyin Mehmet, Director Exploratory Biomarkers, Diabetes, Merck Research Laboratories
• Alison Banham, Nuffield Department of Clinical Laboratory Sciences, Oxford University
• Sanja Selek, Head of Serology and Immune Assays Department, InterCell AG
• Simon Read, Leader Biomarker and Experimental Medicine, F. Hoffmann-La Roche
• Matt Squires, Associate Director Translational Biology, Astex Therapeutics
Early bird discounts are available by quoting “BIO10DEL01”. For information on sponsorship and delegate attendance please email info@oxfordglobal.co.uk or call +44(0) 1865 304925. www.biomarkers-congress.com.
|
|
